RecruitingPhase 2NCT06492837
Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients
Studying Follicular lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Fondazione Italiana Linfomi - ETS
- Principal Investigator
- Marco Ladetto, ProfDepartment of Translational Medicine of the Università degli Studi del Piemonte Orientale, Novara, Italy. AO SS Antonio e Biagio e C. Arrigo, Alessandria, Italy.
- Intervention
- Mosunetuzumab in combination with Zanubrutinib(drug)
- Enrollment
- 56 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2033
Study locations (24)
- Royal Adelaide Hospital, Adelaide, Australia
- Liverpool Hospital, Liverpool, Australia
- St. Vincent Hospital Melbourne, Melbourne, Australia
- Princess Alexandra Hospital, Woolloongabba, Australia
- Fondazione del Piemonte per l'Oncologia - IRCCS, Ematologia, Candiolo, Torino, Italy
- AOU SS. Antonio e Biagio e Cesare Arrigo, SCDU Ematologia, Alessandria, Italy
- AOU Ospedali Riuniti, Clinica di Ematologia, Ancona, Italy
- Azienda Ospedaliera S.Giuseppe Moscati, S.C. Ematologia e Trapianto emopoietico, Avellino, Italy
- IRCCS Istituto Tumori Giovanni Paolo II, U.O.C Ematologia, Bari, Italy
- Policlinico S.Orsola-Malpighi, Istituto di Ematologia "Seragnoli", Bologna, Italy
- ASST Spedali Civili di Brescia, Ematologia, Brescia, Italy
- Azienda Ospedaliera Universitaria Policlinico - S. Marco, UOC di Ematologia, Catania, Italy
- Azienda Ospedaliera Universitaria Careggi, Unità funzionale di Ematologia, Florence, Italy
- ASST Grande Ospedale Metropolitano Niguarda, SC Ematologia, Milan, Italy
- Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Ematologia, Milan, Italy
- +9 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06492837 on ClinicalTrials.govOther trials for Follicular lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07546760A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234AstraZeneca
- RECRUITINGNCT07528781Novel 3-dimensional Echocardiographic Quantification of Mitral Regurgitant VolumeGermans Trias i Pujol Hospital
- RECRUITINGPHASE2NCT07029503Swedish Cardiac And Renal Failure Study-1Karolinska Institutet
- RECRUITINGNCT07154823A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic MalignanciesTempus AI
- RECRUITINGNCT07328035Remission in Adults With Severe Asthma in ThailandThammasat University
- RECRUITINGPHASE3NCT07083154GLP-1/GCG Dual Agonist in Type 2 Diabetes With Early Dementia (LIGHT-COG Study)The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- RECRUITINGPHASE2NCT07128641Odronextamab in Low Tumor Volume Advanced FLGottfried von Keudell, MD PhD
- RECRUITINGPHASE3NCT06911502A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)Celgene